KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 16c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.90), $0.16 better than the analyst estimate of ($1.06).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
• Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
• Morgan Stanley Upgrades M&T Bank (MTB) to Overweight